ARKG Stock Risk & Deep Value Analysis
ARKG
DVR Score
out of 10
What You Need to Know About ARKG Stock
We analyzed ARKG using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran ARKG through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
Get notified when ARKG moves
Same alert types as Telegram — presets or custom thresholds in your 🔔 feed.
📈ARKG Performance Overview3yr weekly
Unlock ARKG Performance Chart
See 3 years of price history, quarterly revenue trends, and DVR score changes
Weekly adjusted close · Quarterly revenue & EPS · DVR score history
ARKG Risk Analysis & Red Flags
What Could Go Wrong
The actively managed nature of ARKG means its performance is highly dependent on ARK Invest's stock-picking ability. Should a significant portion of its concentrated, high-growth holdings fail in clinical trials or face unexpected regulatory hurdles, or if ARK's investment strategy underperforms its peers, the fund's current 20% YTD return could quickly erode, potentially leading to significant capital losses for investors.
Risk Matrix
Overall
Aggressive
Financial
Low
Market
High
Competitive
Medium
Execution
Medium
Regulatory
Medium
Red Flags
- ⚠
Fund Concentration: While not explicitly detailed, active management often implies concentration in high-conviction holdings, increasing volatility compared to broadly diversified ETFs.
- ⚠
Managerial Dependency: The fund's strategy and performance are closely tied to the expertise and decision-making of Cathie Wood and the ARK Invest team, posing a risk should key personnel depart or strategy shift.
- ⚠
No Traditional Corporate Financials: As an ETF, ARKG lacks traditional corporate balance sheet and cash flow statements, making fundamental analysis based on 'health' metrics like debt-to-equity inapplicable in the traditional sense.
- ⚠
Expense Ratio (Implied): Actively managed ETFs typically have higher expense ratios than passive index funds, which over long periods can slightly dilute investor returns (specific ratio not provided but inferred).
Upcoming Risk Events
- 📅
Negative Outcomes from Key Clinical Trials (Next 6-12 months): A top-5 holding failing a critical clinical trial or receiving a 'Refuse to File' letter from the FDA could lead to a significant valuation drawdown for that company, impacting ARKG's NAV.
- 📅
Reversal of FDA Regulatory Stance (Q4 2026 - Q1 2027): Any political or scientific shift leading to a tightening or reversal of the FDA's 'more flexible approach' could dampen biotech sentiment and reduce the likelihood of timely approvals for ARKG's portfolio companies.
When to Reconsider
- 🚪
Underperformance: If ARKG's YTD return falls below that of its closest peer (e.g., XBI or IDNA) for two consecutive quarters, signaling a potential shift in competitive advantage.
- 🚪
Significant Outflows: If the fund experiences net investor outflows exceeding 10% of its Assets Under Management (AUM) in a single quarter, indicating waning investor confidence.
- 🚪
Price Breakdown: A sustained break below $30.00 (approximately a 20% decline from the recent $36.86 close), signaling loss of momentum and a potential shift in market sentiment.
Unlock ARKG Risk Analysis & Red Flags
Create a free account to see the full analysis
Investment Thesis
If the FDA's 'more flexible approach' (June 2026) significantly accelerates clinical trial successes and commercialization pathways for ARKG's underlying innovative biotech holdings, driving substantial revenue growth and market penetration for multiple portfolio companies, then ARKG's NAV could surge, potentially delivering 300-500% returns over 3-5 years as its concentrated bets in multi-billion dollar genomic segments achieve market leadership and generate strong cash flows. This is bullish because the long-term impact of the FDA shift and the full disruptive potential of genomics are likely still underestimated by the broader market.
Is ARKG Stock Undervalued?
Unlock the full AI analysis for ARKG
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
ARKG Price Targets & Strategy
12-Month Target
$60.00
Bull Case
$75.00
Bear Case
$30.00
Valuation Basis
Based on projected 60% NAV growth in 12 months (reflecting continued strong performance of underlying holdings and sustained sector tailwinds) from the $36.86 close on 2026-06-18.
Entry Strategy
Dollar-cost average between $35-$40, ideally buying on dips closer to the $35 support level to capitalize on recent momentum. Current price is $36.86 as of 06/18/2026.
Exit Strategy
Take 50% profit at $60; consider a trailing stop-loss below the 50-day SMA, or at $30 if significant negative news emerges.
Portfolio Allocation
7-15% for aggressive risk tolerance, reflecting its high-risk, high-reward profile and thematic focus.
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is ARKG Financially Healthy?
Valuation
P/E Ratio
-1.96
Forward P/E
-1.96
EV/EBITDA
-1.96
PEG Ratio
-1.96
Price/Book
7.89
Profitability
Gross Margin
-196.00%
Operating Margin
-196.00%
Net Margin
-196.00%
Revenue Growth
-1290.00%
EPS
$-0.00
Balance Sheet
Debt/Equity
-1.96
Total Debt
$12.76
Cash & Equivalents
-$1.96
Cash Flow
Operating Cash Flow
-$1.96
Free Cash Flow
-$1.96
EBITDA
-$1.96
Other
Beta (Volatility)
1.73
Does ARKG Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat's durability depends on ARK Invest's consistent ability to identify and invest in future market leaders in the rapidly evolving genomics sector and to sustain superior returns compared to its passively managed or less agile competitors.
Moat Erosion Risks
- •Underperformance Risk: Prolonged periods of underperformance relative to benchmarks or peers could erode investor confidence and lead to outflows, diminishing brand power.
- •Talent Risk: Departure of key investment professionals, particularly Cathie Wood, could significantly impact the fund's investment strategy and execution.
ARKG Competitive Moat Analysis
Sign up to see competitive advantages
ARKG Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Bullish, largely driven by Cathie Wood's following, ARKG's recent outperformance, and the general excitement around disruptive biotech themes.
Institutional Sentiment
Positive, highlighted by Zacks Investment Research naming ARKG a 'top performer' in 1H 2026 and reporting significant investor inflows.
Insider Activity (Form 4)
ARK Invest actively rebalancing its combined ETF portfolio, filing 15 trades (10 buys, 5 sells) on June 5, 2026, indicating ongoing adjustments to underlying holdings rather than traditional insider buying/selling of ARKG shares.
Options Flow
Normal options activity, with no specific unusual put/call ratio or large block trades explicitly detailed in the provided research.
Earnings Intelligence
Next Earnings
Q2 2026 Performance Summary (Estimated July 2026)
Surprise Probability
High, given its 20% YTD return and recent catalysts, the market may expect continued strong performance.
Historical Earnings Pattern
Likely positive reaction to strong performance updates and positive news regarding underlying holdings, and negative reaction to underperformance or significant outflows.
Key Metrics to Watch
Competitive Position
Top Competitor
IDNA (iShares Genomics Immunology and Healthcare ETF)
Market Share Trend
Gaining, evidenced by its significant outperformance and investor inflows in 1H 2026 relative to peers like XBI, IDNA, GNOM, and BBC.
Valuation vs Peers
ARKG's actively managed nature and outperformance (20% YTD vs IDNA's 14.5% YTD) imply a premium based on perceived alpha generation potential, rather than traditional valuation multiples.
Competitive Advantages
- •Active Management & Research Expertise (ARK Invest's specific investment philosophy and research capabilities).
- •Thematic Focus (Concentration on disruptive genomic technologies, positioning it for long-term trends).
- •Brand Recognition (Cathie Wood's public profile and ARK's track record in identifying innovative companies).
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive ARKG Stock Higher?
Near-Term (0-6 months)
- •Q2 2026 Performance Summary (expected July 2026): A sustained high YTD return could attract further significant inflows and reconfirm investor confidence in ARK's strategy.
- •FDA Clarification on Flexible Approval Process (Q3 2026): Further specific guidelines or approvals for novel genomic therapies under the 'more flexible approach' could accelerate clinical trial success for ARKG's holdings.
Medium-Term (6-18 months)
- •Major Clinical Trial Success by Top Holdings (Q4 2026 - Q2 2027): Successful Phase 3 trial results or breakthrough therapy designations for a top-5 holding (e.g., in gene editing or cell therapy) could trigger a significant re-rating of the overall portfolio value.
- •Increased Strategic M&A in Genomics (12-18 months): Large pharmaceutical companies acquiring smaller, innovative biotech firms within ARKG's portfolio could provide substantial short-term gains for affected holdings.
Long-Term (18+ months)
- •Commercialization of Gene-Editing Therapies (2028-2029): Broad market adoption and insurance coverage for advanced gene-editing or cell therapies could unlock multi-billion dollar markets, driving exponential growth in ARKG's core investments.
- •Integration of AI/ML into Genomic Research (2028-2029): Continued advancements and widespread adoption of AI-driven platforms in drug discovery and personalized medicine by ARKG's holdings could significantly reduce R&D costs and accelerate pipeline development, boosting profitability.
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for ARKG?
- ✓
Quarterly NAV growth: Monitor if ARKG's NAV continues to grow at >15% per quarter, indicating strong underlying portfolio performance.
- ✓
FDA approval announcements: Watch for 3+ major drug/therapy approvals from ARKG's top 10 holdings within the next 12 months, signaling successful execution on the 'flexible approach' catalyst.
Bull Case Analysis
Sign up free to see the bull case
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How ARKG Makes Money
ARKG (ARK Genomic Revolution ETF) is an actively managed exchange-traded fund that provides investors with exposure to companies driving the 'Genomic Revolution.' This involves firms engaged in gene sequencing, gene editing, bioinformatics, and agricultural biology, aiming for long-term capital growth. The fund generates revenue by charging a management fee (expense ratio) on the total assets it manages, essentially making money from investors' capital allocated to its thematic strategy.
Read Full Business Model BreakdownFAQ
What is the DVR Score for ARKG (ARKG)?
As of June 24, 2026, ARKG has a DVR Score of 9.2 out of 10, placing it in the "Hidden Gem" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of ARKG?
ARKG's market capitalization is approximately $10.27..
What is the risk level for ARKG stock?
Our analysis rates ARKG's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of ARKG?
ARKG currently has a price-to-earnings (P/E) ratio of -2.0. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is ARKG's revenue growing?
ARKG has reported revenue growth of -1290.0%. Revenue has been declining, which warrants closer examination.
Is ARKG stock profitable?
ARKG has a profit margin of -196.0%. The company is currently unprofitable.
How often is the ARKG DVR analysis updated?
Our AI-powered analysis of ARKG is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on June 24, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for ARKG (ARKG) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.